Literature DB >> 22524419

Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein.

Yu Saito1, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Shinichiro Yamada, Michihito Asanoma.   

Abstract

AIM: Lens culinaris agglutinin A-reactive fraction of α-fetoprotein (AFP-L3) status has been reported to be an independent prognostic factor in patients with hepatocellular carcinoma (HCC). In this study, we evaluated the clinical usefulness of measuring preoperative AFP-L3 to predict the recurrence and prognosis of HCC after curative hepatectomy.
METHODS: One hundred and forty-two HCC patients who underwent curative hepatectomy were examined for the correlation between preoperative tumor marker, including AFP, des-γ-carboxy prothrombin (DCP) and AFP-L3, and clinicopathological variables. The prognostic factors of disease-free survival rates and overall survival rates were also determined using clinicopathological variables including these three tumor markers.
RESULTS: There were similar tendencies in the relationship between these three markers and malignant behaviors including lower grade tumor differentiation or vascular invasion. In multivariate analysis, increased AFP-L3 value (P = 0.019) was found to be an independent prognostic factor of disease-free survival after curative hepatectomy. In addition, elevated DCP (P = 0.013) and AFP-L3 values (P = 0.012) were found to be independent prognostic factors. Furthermore, the preoperative AFP-L3 value in the patients with early recurrence (within 1 year after hepatectomy) was significantly higher than that in those without early recurrence (26.9 ± 19.5 % vs 14.2 ± 19.8 %, P = 0.047).
CONCLUSION: Preoperative AFP-L3 value was strongly correlated to disease-free and overall survival rate and the timing of recurrence, so it appears that it would be useful to predict the recurrence and prognosis of HCC after curative hepatectomy.
© 2012 The Japan Society of Hepatology.

Entities:  

Year:  2012        PMID: 22524419     DOI: 10.1111/j.1872-034X.2012.01004.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  15 in total

Review 1.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.

Authors:  Makoto Meguro; Toru Mizuguchi; Toshihiko Nishidate; Kenji Okita; Masayuki Ishii; Shigenori Ota; Tomomi Ueki; Emi Akizuki; Koichi Hirata
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

5.  Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria.

Authors:  Satoru Imura; Hiroki Teraoku; Masato Yoshikawa; Daichi Ishikawa; Shinichiro Yamada; Yu Saito; Shuichi Iwahashi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2017-09-05       Impact factor: 3.402

Review 6.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

7.  FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC.

Authors:  Yue Zhang; Zhifan Zuo; Bo Liu; Pinghua Yang; Jun Wu; Lei Han; Tao Han; Tingsong Chen
Journal:  J Gastrointest Oncol       Date:  2021-08

8.  A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.

Authors:  Chuan Jin; Jian-Sen Zhao; Xu-Qi Huang; Xian-Zi Yang; Feng Li; Ye Song; Fei-Yu Niu; Jin-Rong Lin; Lei Ma; Yan-Xia Shi; Xiao-Shan Li; Peng Jiang; Sha Gao
Journal:  Hepatol Int       Date:  2022-08-10       Impact factor: 9.029

9.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

Review 10.  Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.

Authors:  Yuan-Mao Lin; Ryosuke Taiji; Marco Calandri; Bruno C Odisio
Journal:  Curr Oncol Rep       Date:  2021-04-15       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.